Discontinued — last reported Q1 '23
Products & Services · Research and development expense
ADUHELM — Research and development expense
Biogen ADUHELM — Research and development expense increased by 857.1% to $335.00M in Q1 2023 compared to the prior quarter.
Analysis
StatementSegment
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ3 2022
Last reportedQ1 2023
Rolls up toR&D
How to read this metric
High spending indicates a commitment to innovation, but sustained high levels without revenue growth may signal inefficiency.
Detailed definition
This metric captures the total costs incurred for the research, development, and clinical trials of a specific product o...
Peer comparison
Benchmark against industry peers in biotechnology to assess R&D efficiency relative to pipeline success.
Metric ID:
biib_segment_aduhelm_research_and_development_expenseHistorical Data
3 periods
| Q3 '22 | Q4 '22 | Q1 '23 | |
|---|---|---|---|
| Value | $25.00M | $35.00M | $335.00M |
| QoQ Change | — | +40.0% | +857.1% |
Range$25.00M – $335.00M
Current Streak2+ quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's aduhelm — research and development expense?
- Biogen (BIIB) reported aduhelm — research and development expense of $335.00M in Q1 2023.
- What does aduhelm — research and development expense mean?
- The total spending on research and development for a specific product.